The PREMM(1,2,6) model predicts risk of MLH1, MSH2, and MSH6 germline mutations based on cancer history.

BACKGROUND & AIMS We developed and validated a model to estimate the risks of mutations in the mismatch repair (MMR) genes MLH1, MSH2, and MSH6 based on personal and family history of cancer. METHODS Data were analyzed from 4539 probands tested for mutations in MLH1, MSH2, and MSH6. A multivariable polytomous logistic regression model (PREMM(1,2,6)) was developed to predict the overall risk of MMR gene mutations and the risk of mutation in each of the 3 genes. The discriminative ability of the model was validated in 1827 population-based colorectal cancer (CRC) cases. RESULTS Twelve percent of the original cohort carried pathogenic mutations (204 in MLH1, 250 in MSH2, and 71 in MSH6). The PREMM(1,2,6) model incorporated the following factors from the probands and first- and second-degree relatives (odds ratio; 95% confidence intervals [CIs]): male sex (1.9; 1.5-2.4), a CRC (4.3; 3.3-5.6), multiple CRCs (13.7; 8.5-22), endometrial cancer (6.1; 4.6-8.2), and extracolonic cancers (3.3; 2.4-4.6). The areas under the receiver operating characteristic curves were 0.86 (95% CI, 0.82-0.91) for MLH1 mutation carriers, 0.87 (95% CI, 0.83-0.92) for MSH2, and 0.81 (95% CI, 0.69-0.93) for MSH6; in validation, they were 0.88 for the overall cohort (95% CI, 0.86-0.90) and the population-based cases (95% CI, 0.83-0.92). CONCLUSIONS We developed the PREMM(1,2,6) model, which incorporates information on cancer history from probands and their relatives to estimate an individual's risk of mutations in the MMR genes MLH1, MSH2, and MSH6. This Web-based decision making tool can be used to assess risk of hereditary CRC and guide clinical management.

[1]  Finlay Macrae,et al.  Risks of Lynch syndrome cancers for MSH6 mutation carriers. , 2010, Journal of the National Cancer Institute.

[2]  Ewout W Steyerberg,et al.  Prediction of MLH1 and MSH2 mutations in Lynch syndrome. , 2006, JAMA.

[3]  E. Steyerberg,et al.  Phenotype Comparison of MLH1 and MSH2 Mutation Carriers in a Cohort of 1,914 Individuals Undergoing Clinical Genetic Testing in the United States , 2008, Cancer Epidemiology Biomarkers & Prevention.

[4]  L. Aaltonen,et al.  Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. , 2000, Gastroenterology.

[5]  M. Woods,et al.  Prediction of Lynch syndrome in consecutive patients with colorectal cancer. , 2009, Journal of the National Cancer Institute.

[6]  E. Steyerberg,et al.  Validation and extension of the PREMM1,2 model in a population-based cohort of colorectal cancer patients. , 2008, Gastroenterology.

[7]  C. Boland,et al.  A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. , 1997, Journal of the National Cancer Institute.

[8]  P. Møller,et al.  Familial endometrial cancer in female carriers of MSH6 germline mutations , 1999, Nature Genetics.

[9]  Ewout W Steyerberg,et al.  Data reduction for prediction: A case study on robust coding of age and family history for the risk of having a genetic mutation , 2007, Statistics in medicine.

[10]  E. Steyerberg.  Clinical Prediction Models , 2008, Statistics for Biology and Health.

[11]  M. Kloor,et al.  Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  A. Rustgi,et al.  The Hereditary Nonpolyposis Colorectal Cancer Syndrome: Genetics and Clinical Implications , 2003, Annals of Internal Medicine.

[13]  L. Irwig,et al.  Assessing new biomarkers and predictive models for use in clinical practice: a clinician's guide. , 2008, Archives of internal medicine.

[14]  J. Kleibeuker,et al.  Decrease in mortality in Lynch syndrome families because of surveillance. , 2006, Gastroenterology.

[15]  J. Mecklin,et al.  The International Collaborative Group on HNPCC. , 1994, Anticancer research.

[16]  W. Grady.  Genetic testing for high-risk colon cancer patients. , 2003, Gastroenterology.

[17]  W. Foulkes,et al.  A comparison of models used to predict MLH1, MSH2 and MSH6 mutation carriers. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  H T Lynch,et al.  New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. , 1999, Gastroenterology.

[19]  D. Horsman,et al.  Validation of predictive models for germline mutations in DNA mismatch repair genes in colorectal cancer , 2009, International journal of cancer.

[20]  M. von Knebel Doeberitz,et al.  Lower incidence of colorectal cancer and later age of disease onset in 27 families with pathogenic MSH6 germline mutations compared with families with MLH1 or MSH2 mutations: the German Hereditary Nonpolyposis Colorectal Cancer Consortium. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  E. Steyerberg,et al.  Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients with Lynch syndrome in a population-based cohort of colorectal cancer patients , 2008, Journal of Medical Genetics.

[22]  M. Munsell,et al.  Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. , 2006, The New England journal of medicine.

[23]  J. Mecklin,et al.  The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC) , 1991, Diseases of the colon and rectum.

[24]  Sudhir Srivastava,et al.  Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. , 2004, Journal of the National Cancer Institute.

[25]  John D Potter,et al.  Colon Cancer Family Registry: An International Resource for Studies of the Genetic Epidemiology of Colon Cancer , 2007, Cancer Epidemiology Biomarkers & Prevention.

[26]  G. Parmigiani,et al.  Whole pelvic helical tomotherapy for locally advanced cervical cancer: technical implementation of IMRT with helical tomothearapy , 2009, Radiation oncology.

[27]  Bhramar Mukherjee,et al.  Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. , 2009, Gastroenterology.

[28]  Peter Beighton,et al.  de la Chapelle, A. , 1997 .

[29]  Harry Campbell,et al.  Identification and survival of carriers of mutations in DNA mismatch-repair genes in colon cancer. , 2006, The New England journal of medicine.

[30]  A. de la Chapelle,et al.  Hereditary Colorectal Cancer , 2010 .